It appears that utilization of VEGF as a potential treatment option for DMD patients has to be carefully considered, especially taking into account the dosage of VEGF being used, as its over-administration might exert severe adverse effects, ranging from edema or hemangioma formation [103, 104] to the development of endothelial cell-derived vascular tumors [105]. The gene discussed is VEGFA; the disease is Duchenne muscular dystrophy.